Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 243,291,808
  • Shares Outstanding, K 2,262,969
  • Annual Sales, $ 22,401 M
  • Annual Income, $ 7,598 M
  • 60-Month Beta 0.44
  • Price/Sales 10.57
  • Price/Cash Flow 28.79
  • Price/Book 22.23
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 25.26% ( -1.44%)
  • Historical Volatility 46.93%
  • IV Percentile 23%
  • IV Rank 17.87%
  • IV High 41.54% on 04/26/22
  • IV Low 21.72% on 08/27/21
  • Put/Call Vol Ratio 0.46
  • Today's Volume 884
  • Volume Avg (30-Day) 1,375
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 43,550
  • Open Int (30-Day) 37,502

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.87
  • Number of Estimates 3
  • High Estimate 0.88
  • Low Estimate 0.86
  • Prior Year 0.84
  • Growth Rate Est. (year over year) +3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.37 +9.48%
on 08/03/22
117.42 -7.35%
on 08/01/22
-0.75 (-0.68%)
since 07/11/22
3-Month
99.37 +9.48%
on 08/03/22
117.42 -7.35%
on 08/01/22
+4.98 (+4.80%)
since 05/11/22
52-Week
91.51 +18.88%
on 01/24/22
122.16 -10.94%
on 04/07/22
+8.06 (+8.00%)
since 08/11/21

Most Recent Stories

More News
Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

RHHBY : 41.0400 (-2.49%)
BMY : 74.46 (-0.53%)
NVO : 108.79 (+1.19%)
PRTA : 31.28 (-1.57%)
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates

Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

NVO : 108.79 (+1.19%)
BEAM : 66.09 (+0.55%)
ATRA : 4.65 (-6.06%)
DTIL : 1.6300 (-1.21%)
Novo Nordisk (NVO) Q2 2022 Earnings Call Transcript

NVO earnings call for the period ending June 30, 2022.

NVO : 108.79 (+1.19%)
Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More

Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.

NVO : 108.79 (+1.19%)
LLY : 301.17 (-1.13%)
AMGN : 248.35 (-1.48%)
VRTX : 292.16 (-1.22%)
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?

Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.

NVO : 108.79 (+1.19%)
GILD : 62.45 (-1.09%)
HZNP : 67.10 (-1.91%)
BNTX : 158.59 (-1.45%)
Alnylam's Strategy Is Getting Bigger. Time to Buy?

After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.

ALNY : 229.39 (-1.13%)
NVS : 85.58 (-2.12%)
NVO : 108.79 (+1.19%)
1 Cheap Medical Stock With Strong Upside Potential

Assertio Holdings (ASRT) has achieved significant product and service advancements and increased its market reach over the past few months. Furthermore, it has solid fundamentals and is currently trading...

ASRT : 3.80 (-5.00%)
MRK : 88.93 (-0.29%)
NVO : 108.79 (+1.19%)
PFE : 48.29 (-3.32%)
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease

Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...

CRDL : 1.1600 (unch)
CRDL.TO : 1.44 (-4.00%)
JNJ : 167.14 (-2.07%)
TAK : 14.12 (-0.70%)
NVO : 108.79 (+1.19%)
BMY : 74.46 (-0.53%)
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease

/PRNewswire/ -- As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, the concern that it could increase...

CRDL.TO : 1.44 (-4.00%)
JNJ : 167.14 (-2.07%)
TAK : 14.12 (-0.70%)
NVO : 108.79 (+1.19%)
BMY : 74.46 (-0.53%)
CRDL : 1.1600 (unch)
3 Stocks No One Is Talking About but Should Be

Amid an uncertain market, it becomes increasingly difficult for investors to find stocks that can survive the challenges and deliver solid returns. Accel Entertainment (ACEL), Novo Nordisk (NVO), and Titan...

ACEL : 9.92 (+4.31%)
NVO : 108.79 (+1.19%)
TITN : 30.31 (+1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 112.65
2nd Resistance Point 111.54
1st Resistance Point 110.16
Last Price 108.79
1st Support Level 107.67
2nd Support Level 106.56
3rd Support Level 105.18

See More

52-Week High 122.16
Fibonacci 61.8% 110.45
Last Price 108.79
Fibonacci 50% 106.84
Fibonacci 38.2% 103.22
52-Week Low 91.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar